Exonhit, Pfizer Collaborate on Alzheimer's Biomarkers | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Exonhit today announced a deal with Pfizer for use of Exonhit's technology for identifying biomarkers associated with Alzheimer's disease.

Exonhit's Genome-Wide SpliceArray platform will be used to identify progression and other biomarkers "that could segregate healthy elderly controls, patients with mild cognitive impairment … and patients with AD," the Paris-based company said.

Pfizer will provide samples from each of the three patient groups for the study.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.